Cytokinetics to Present Phase IIa Clinical Trials Data on Omecamtiv Mecarbil at the 2009 Heart Failure Society of America Annual Meeting
Poster Presentations
Abstract #213: "An Analysis of the Response to CK-1827452, a Selective Cardiac Myosin Activator, in Stable Heart Failure Patients Stratified by Baseline Cardiac Function" is scheduled to be displayed on Monday, September 14, 2009 from 9 AM - 7 PM Eastern Daylight Time (EDT) in Exhibit Hall C. The poster will be moderated by Fady Malik, MD, PhD, FACC, Vice President, Biology and Therapeutics, Cytokinetics, Inc., South San Francisco, California from 5:45-6:45 PM EDT.
Abstract #219: "Phase II Safety Study Evaluating the Novel Cardiac Myosin Activator, CK-1827452, in Patients with Ischemic Cardiomyopathy and Angina" is scheduled to be displayed on Tuesday, September 15, 2009 from 9 AM - 7 PM Eastern Daylight Time (EDT) in Exhibit Hall C. The poster will be moderated by Will Chou, MD, Medical Director, Cytokinetics, Inc., South San Francisco, California from 5:45-6:45 PM EDT.
Abstract #227: "Echocardiographic Detection of Increases in Ejection Fraction in Patients with Heart Failure Receiving the Selective Cardiac Myosin Activator, CK-1827452" is scheduled to be displayed on Tuesday, September 15, 2009 from 9 AM - 7 PM Eastern Daylight Time (EDT) in Exhibit Hall C. The poster will be moderated by Jonathan Goldman, MD, FACC, Chief Medical Officer and Senior Vice President, ICON Medical Imaging, Warrington, Pennsylvania from 5:45-6:45 PM EDT.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' cardiac muscle contractility program is focused on cardiac muscle myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics' lead compound from this program, omecamtiv mecarbil (formerly CK-1827452), a novel small molecule cardiac muscle myosin activator, is in Phase II clinical trials for the potential treatment of heart failure. In May 2009, Amgen Inc. exercised an option to obtain an exclusive worldwide (excluding Japan) license to this program, which includes rights to develop and commercialize omecamtiv mecarbil and related compounds. Under this agreement, Amgen has assumed responsibility for development and commercialization of omecamtiv mecarbil and related compounds, at its expense, subject to specified development and commercialization participation rights of Cytokinetics. In June 2009, Cytokinetics initiated a Phase I clinical trial of CK-2017357, a fast skeletal muscle troponin activator, in healthy volunteers in the United States. CK-2017357 is being developed as a potential treatment for diseases and medical conditions associated with aging, muscle wasting, and neuromuscular dysfunction. In January 2009, Cytokinetics announced the selection of a potential drug candidate directed towards smooth muscle contractility. Cytokinetics' smooth muscle myosin inhibitors have arisen from research focused towards potential treatments for diseases and conditions, such as systemic hypertension, pulmonary arterial hypertension or bronchoconstriction.
Cytokinetics' cancer development programs are focused on mitotic kinesins, a family of motor proteins essential to cell division. Cytokinetics is developing two drug candidates from this program, ispinesib and SB-743921, each an inhibitor of kinesin spindle protein. In addition, Cytokinetics and GlaxoSmithKline are collaborating on research and development activities focused on GSK-923295, an inhibitor of centromere-associated protein E (CENP-E).
All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
Contact:
Christopher S. Keenan
Director, Investor & Media Relations
(650) 624-3000
SOURCE: Cytokinetics, Inc.